DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Acceswire

American Rebel

0.11%

American Rebel Holdings, Inc. Warrants

-5.88%

Actelis Networks

-2.92%

BIO-key International

+3.71%

Callan JMB Inc. Common Stock

-7.78%

ATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.

More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.

Below is the current list of companies confirmed to present and take meetings. Public companies are listed with their exchange and ticker symbol to facilitate investor discovery; private companies are noted accordingly.

Confirmed Presenting Companies

180 Smoke Vape Company (Private)
20/20 Biolabs, Inc. (Private)
51 Talk Online Education Group (NYSE:COE)
ACCESS Newswire (NYSE:ACCS)
Actelis Networks
Alpha Tau
American Critical Resources (Private)
American Rebel Holdings
Angiex Inc. (Private)
Atlas Salt
Aura Systems Inc.
BIO-Key
Biomed Consulting (Private)
BitFuFu
Blykalla (Private)
BrandPilot
Btab Ecommerce Group
C6 Capital (Private)
Callan JMB
Charlie's Holdings, Inc.
Click IT by Motherboard, Inc. (Private)
Datavault AI Inc.
Digital Landia Holding Corp. (Private)
Energea (Private)
Ethema Health Corporation
FendX Technologies Inc. (Frankfurt:FDXTF)
FibroBiologics
First Phosphate Corp.
Fresh Road Health (Private)
Functional Brands
Genvor Incorporated (OTCQB:GNVR)
GF Sports and Entertainment (Private)
Grown Rogue
Harlem Park Partners (Private)
HD Medical (Private)
Healthcare Triangle, Inc.
Helio Corporation
Hotel Communication Network (Private)
IMEX USA, Inc. (Private)
Indonesia Energy Corp Ltd. (NYSE:INDO)
Innovotech (TSXV:IOT.V)
Jupiter Neurosciences, Inc.
Kairos Pharma (NYSE:KAPA)
Kidoz (TSX:KDOZF)
Kragon Space Inc. (Private)
Live Trained LLC (Private)
Lixte Biotechnology Holdings Inc.
Lomiko Metals Inc.
MDWerks Inc.
Mind Pharmaceuticals (Private)
My Size, Inc.
NanoViricides, Inc. (NYSE:NNVC)
Nano Fixation Inc. (Private)
Neopharma Technologies (Private)
Nerds OnSite
New Horizon Aircraft Ltd.
Nomadar
Ocean Power Technologies (NYSE:OPTT)
OwlTing Group
Pacific Rim Energy (Private)
Pan Global Resources Inc.
Perfect Corp.
PetVivo Holdings
Phio Pharmaceuticals Corp.
POSH (Private)
Prairie Operating Co.
Precipio
SafeSpace Global Corporation
Scienjoy Holding Corp.
Shieldwise, Inc. (Private)
Snow Lake Resources Ltd.
Society Pass Inc.
Soligenix, Inc.
Soteria Battery Innovation Group (Private)
Standard Premium Finance Holdings, Inc.
Stewards (Private)
SunScout Holding Limited (Private)
TEN Holdings, Inc.
Tigo Energy
Tivic Health Systems
Token Communities
TRX Gold (NYSE:TRX)
Various Ventures (Private)
Volt Resources Ltd.
Walk-In Dermatology (Private)
WellCare Today (Private)
Wellgistics Health, Inc.
Westwater Resources (NYSE:WWR)
ZenaTech Inc.
Zerostack
Zhittya Genesis Medicine (Private)

The DealFlow Discovery Conference is known for its open-access format, combining formal company presentations with curated 1:1 meetings that allow investors and analysts to engage directly with management teams across public and private markets.

For full conference details, registration information, and updates to the presenting company roster, visit https://dealflowdiscoveryconference.com.

Media Contact / Press Pass Requests:

Phill LoFaso

DealFlow Events

Email: phillip@dealflowevents.com

Journalists interested in attending the conference are encouraged to reach out to request a press pass.

About DealFlow Events

DealFlow Events produces leading capital markets conferences connecting public and private companies with investors, analysts, and intermediaries across growth sectors and asset

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Datavault AI (NASDAQ: DVLT) Closes Acquisition of API Media Innovation

FinanceWire

WiSA Technologies

-3.45%

Austin, Texas, United States, January 23rd, 2026, FinanceWire

Datavault AI , a leader in data monetization, credentialing, digital engagement and real-world asset tokenization technologies, announced that it has closed its previously announced acquisition of API Media Innovation Inc., a New Jersey–headquartered provider of media infrastructure and event technology solutions serving high-profile sports, media and entertainment clients, a transaction the company expects to strengthen its proprietary data-monetization ecosystem through expanded capabilities in multi-channel engagement, data overlay integration, digital media operations, audience intelligence and revenue analytics, while positioning Datavault AI to enhance enterprise value delivery across data, advertising and AI-as-a-Service verticals.

To view the full press release, visit https://ibn.fm/AscmN

About Datavault AI Inc.

Datavault AI is leading the way in AI experience, valuation, and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT

Contact

IBN

www.InvestorBrandNetwork.com

Editor@InvestorBrandNetwork.com

Risk Warnings and Disclaimers

Add to Favorites

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

FinanceWire

Lixte Biotechnology

-4.86%

Lixte Biotechnology Holdings, Inc. Warrants

0.00%

Austin, Texas, United States, January 23rd, 2026, FinanceWire

LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments
Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile
The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise

LIXTE Biotechnology is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target.

LIXTE’s platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A (“PP2A”). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective…

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT

Contact

IBN

www.InvestorBrandNetwork.com

Editor@InvestorBrandNetwork.com

Risk Warnings and Disclaimers

Add to Favorites